My Lords, I thank the Minister for his extremely good introduction to the Bill, He has taken to the job incredibly quickly, taking on this massive Bill so enthusiastically; it is incredibly impressive. I also make a personal testimony to the noble Lord, Lord Stevens, who I knew from the battle against the pandemic over the last two years. His expertise and experience were brought to bear against that awful disease, and I am so pleased to see him now in the Chamber contributing to this important debate.
The Minister is right: this is a proportionate and welcome Bill that enables us to make important changes. The noble Lord, Lord Stevens, is right that it came originally from the health and care system. We should remember that when we comment on it, because it is an omnibus Bill that gives those at the front line the tools they need to improve the system. I completely endorse those who have spoken about the importance of collaboration. My noble friend Lady Harding spoke much more fluently than I possibly could. Medical clinical care very often involves complex issues that need a huge amount of collaboration and work to succeed. Therefore, this Bill should try to smooth out anything that creates inadvertent competition, barriers to discussion or hurdles to getting things done. I think that it gives the system the tools to be able to do that.
I also endorse those who have talked about the importance of prevention. The noble Baroness, Lady Cavendish, is absolutely right; the noble Lord, Lord Stevens, called it a challenge that many advanced economies are facing and he is entirely right. Prevention is key. The pandemic showed us that our current health system is living beyond its means, and we have nothing but challenges ahead of us. The population health measures enabled by the ICSs are potentially critically important. This Bill only enables that potential; I would endorse its power and encourage the Minister to run really hard at prevention.
That is why I support Clause 4 on cancer detection, which was introduced in the other place. It touches on the point referred to by the noble Baroness, Lady Cavendish; by putting an emphasis on outcomes rather than the operational details of cancer detection, it is trying to introduce an important inflection point that I think could be duplicated elsewhere. That is also why I support Schedule 17 on junk food advertising; we have to seize the nettle on that. There was so much sadness in the daily meetings that I used to attend in ICU units. When the numbers of people being intubated were ticking up, so often they were because of comorbidities created by overweight. We need to tackle our obesity epidemic; that is why Schedule 17 is so important. I would also endorse those who have supported the work on hymenoplasty; while I welcome the Government’s moves in this area so far, I think they can go further.
What I really want to endorse is innovation. Data has been mentioned by a large number of noble Lords. The noble Baroness, Lady Cavendish, talked a bit about productivity; the noble Baroness, Lady Barker, talked about patient care; one noble Lord talked about safety. They are all absolutely right. Clauses 81 to 87 in Part 2 are critical, and I would like to hear the Minister’s endorsement of those. I also support the commitment to research. The noble Lord, Lord Kakkar, spoke very well—much better than I could—about the case for strengthening ICSs’ commitment to research. If the NHS is to achieve what it needs to achieve, it needs to double down on its ability to deliver research; this is an area that the Minister should very firmly commit to looking at, as the Bill makes its progress.
6.14 pm